

## Pathogenreduktion von Blutprodukten – ein Paradigmenwechsel in der Transfusionsmedizin

- 1) Engelfriet CP, Reesink HW, Snyder EL, Dzik WH, Masse M, Naegelen C, Brand A, Williamson L, Knipe J, Bruce M, Woodfield DG, Sekiguchi S, Myllyla G, Sablinski J, Zupanska B:  
*The official requirements for platelet concentrates.*  
*Vox Sang* 1998;**75**:308-317.
- 2) Devine DV, Bradley AJ, Maurer E, Levin E, Chahal S, Serrano K, Gyongyossy-Issa MI:  
*Effects of prestorage white cell reduction on platelet aggregate formation and the activation state of platelets and plasma enzyme systems.*  
*Transfusion* 1999;**39**:724-734.
- 3) Harrington T, Kuehnert MJ, Kamel H, Lanciotti RS, Hand S, Currier M, Chamberland ME, Petersen LR, Marfin AA:  
*West Nile virus infection transmitted by blood transfusion.*  
*Transfusion* 2003;**43**:1018-1022.
- 4) Bianco C:  
*Dengue and Chikungunya viruses in blood donations: risks to the blood supply?*  
*Transfusion* 2008;**48**:1279-128.
- 5) Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F:  
*Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.*  
*Transfusion* 2007;**47**:2338-2347.
- 6) Pereira A:  
*Methylene-blue-photoinactivated plasma and its contribution to blood safety.*  
*Transfusion* 2004;**44**:948-950; author reply 950.
- 7) Pelletier JP, Transue S, Snyder EL:  
*Pathogen inactivation techniques.*  
*Best Pract Res Clin Haematol* 2006;**19**:205-242.
- 8) Irsch J, Lin L:  
*Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™.*  
*Transfusion Medicine and Hemotherapy* 2011;**38**:19-31.
- 9) Marschner S, Goodrich R:  
*Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.*  
*Transfusion Medicine and Hemotherapy* 2011;**38**:8-18.
- 10) Seltsam A, Mueller TH:  
*UVC irradiation for pathogen reduction of platelet concentrates and plasma.*  
*Transfus Med Hemother* 2011;**38**:43-54.
- 11) Henschler R, Seifried E, Mufti N:  
*Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates.*  
*Transfusion Medicine and Hemotherapy* 2011;**38**:33-42.
- 12) Schlenke P, Hervig T, Isola H, Wiesel ML, Kientz D, Pinkoski L, Singh Y, Lin L, Corash L, Cazenave JP:  
*Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers.*  
*Transfusion* 2008;**48**:697-705.
- 13) Ettinger A, Miklaur MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP:  
*Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 degrees C.*  
*Transfus Apher Sci* 2011;**44**:25-31.

- 14) Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, Burks S, Wages D, Van Doren S, Corash L: Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. *Blood* 2006.
- 15) Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG: A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. *Transfusion* 2006;**46**:1693-1704.
- 16) Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, Propst M, Liu W, Corash L, Sundin D, Defoin L, Messe N, Osselaer JC: An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. *Transfusion* 2010;**50**:1210-1219.
- 17) McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard Ft, Davis K, Lin JS, Metzler P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. *Blood* 2004;**104**:1534-1541.
- 18) van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marble S, Mayaudon V, Flament J, Conlan M, Lin L, Metzler P, Buchholz D, Corash L: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euro-SPRITE trial. *Blood* 2003;**101**:2426-2433.
- 19) Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ: Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. *Br J Haematol* 2010;**150**:209-217.
- 20) A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. *Transfusion* 2010;**50**:2362-2375.
- 21) Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, Raidot JP, Kandel G, Wiesel ML, Corash L: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. *Transfusion* 2011;**51**:622-629.
- 22) Gelderman MP, Chi X, Zhi L, Vostal JG: Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion. *Transfusion* 2011.
- 23) Corash L, Lin JS, Sherman CD, Eiden J: Determination of acute lung injury after repeated platelet transfusions. *Blood* 2011;**117**:1014-1020.
- 24) Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG: Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. *Transfusion* 2005;**45**:1739-1749.
- 25) North AK, Henschler R, Geisen C, Garratty G, Arndt PA, Kattamis A, Cohen A, Piga A, Arslan O, Galanello R: Evaluation of naturally occurring antibodies to pathogen inactivated red blood cells. *Transfusion* 2010;**50** (suppl):38A.

- 
- 26) Festlegung der Haltbarkeitsfrist von Thrombozytenkonzentraten mit dem Ziel der Reduktion lebensbedrohlicher septischer Transfusionsreaktionen durch bakterielle Kontamination.  
*Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz* 2008;**51**:1484.
- 27) Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP: Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion.  
*Transfusion* 2009;**49**:1083-1091.
- 28) Goodrich RP, Gilmour D, Hovenga N, Keil SD:  
A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns.  
*Transfusion* 2009.
- 29) Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, Muller TH, Volker U:  
A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light.  
*Transfusion* 2009;**49**:2612-2624.
- 30) Kleinman S, Cameron C, Custer B, Busch M, Katz L, Kralj B, Matheson I, Murphy K, Preiksaitis J, Devine D:  
Modeling the risk of an emerging pathogen entering the Canadian blood supply.  
*Transfusion* 2010;**50**:2592-2606.
- 31) Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U:  
Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.  
*Transfus Med* 2005;**15**:379-387.
- 32) Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA:  
Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands.  
*Transfusion* 2006;**46**:956-965.